<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03929107</url>
  </required_header>
  <id_info>
    <org_study_id>lymphoma center Q003</org_study_id>
    <nct_id>NCT03929107</nct_id>
  </id_info>
  <brief_title>Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma.</brief_title>
  <official_title>Interleukin-7 and Chemokine (C-C Motif) -Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wenbin Qian</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhejiang Provincial Tongde Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>First Affiliated Hospital of Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It's a single arm, open label prospective study, in which the safety and efficacy of
      Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T therapy are evaluated
      in refractory/relapsed B cell lymphoma patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 28, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete remission rate</measure>
    <time_frame>at the time point 3 months after CAR-T cell transfusion</time_frame>
    <description>complete remission rate after treated by CAR-T therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>adverse events</measure>
    <time_frame>from the date of the start of treatment to 24 months after last patient's enrollment</time_frame>
    <description>any unfavorable and unintended sign , symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free surviva</measure>
    <time_frame>from the day of treatment to the date of first documented progression，up to 24 months after the last patient's enrollment</time_frame>
    <description>from date of inclusion to date of progression, relapse, or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>from the day of treatment to the date of first documented progression，up to 24 months after the last patient's enrollment</time_frame>
    <description>from the date of inclusion to date of death, irrespective of cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of the CAR-T cells in the patients</measure>
    <time_frame>from the date of re-transfusison to 24 months after last patient's enrollment</time_frame>
    <description>time from re-transfusion to date when the modified T cells become non-detectable.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>B Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, patients will be treated with Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T, and the safety and efficacy will be evaluated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells</intervention_name>
    <description>patient's T cells were seperated and engineered into Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells, and retransfused into the patient for treatment of their B cell lymphoma.</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Age 18-75 years old, male or female;

          -  2. ECOG 0-3, for patients with ECOG=4, if ECOG reach 0-3 after bridging treatment with
             ibrutinib, they are also considered to fit this criteria;

          -  3. Histologically diagnosed as B cell non-Hodgkin's lymphoma (NHL)(according to WHO
             2008 criteria), including DLBCL-NOS, primary mediastinal B cell lymphoma (PMBCL)
             mantel cell lymphoma (MCL), transformed follicular lymphoma (TFL) and other
             transformed B cell NHL;

          -  4. CD19 positive (by immuno-histology or flowcytometry) [for DLBCL/PMBCL/TFL patients,
             negative CD19 immuno-histology results also acceptable];

          -  5. Definition of relapsed and refractory disease: 1) refractory DLBCL should fit one
             of the following: ①complete remission NOT achieved after 2nd line treatment;
             ②progression of disease during treatment; ③duration of stable disease ＜6 months; ④
             disease progress or relapse within 12 months of autologous stem cell transplantation.

             2) definition of refractory/relapsed disease for CLL and other indolent B cell NHL,
             should fit one of the following: ① failed or relapsed after 2nd therapy (Rituximab
             must be included) and being unable to accept ibrutinib treatment due to various
             reasons; ② non-responsive or intolerable to ibrutinib as 2nd line treatment; 3)
             refractory or relapsed MCL should fit one of the following: ① complete remission not
             achieved after 2nd line treatment; ② disease progression during treatment; ③duration
             of stable disease ≤6 months; ④disease progress or relapse within 12 months of
             autologous stem cell transplantation.

          -  6. Previous treatment of aggressive B lymphomas must include Rituximab and
             anthracyclines;

          -  7. Patients should have at least one measurable disease focus, with the longitudinal
             diameter ≥1.5cm, or any extra-nodal focus with the longitudinal diameter ≥1.0cm, with
             PET/CT positive results;

          -  8. Blood routine test, absolute neutrophil count≥1000/ul、platelet count≥45000/ul；

          -  9. Cardiac, hepatic and renal function: Creatinin ＜1.5 times of normal maximum；ALT/AST
             level ＜2.5 times of the maximum of normal range; total bilirubin＜1.5 times of
             ULN；cardiac ejection fraction≥ 50%;

          -  10. Patients should have the ability to fully understand contents of the written
             consent and be willing to sign the written consent;

          -  11. Fertile patients should agree to take contraceptive measures during the process of
             this trial.

        Exclusion Criteria:

          -  1. History of other malignant tumor;

          -  2. History of autologous stem cell transplantation within 6 weeks prior to enrollment;

          -  3. Received CAR-T therapy within 3 months prior to enrollment;

          -  4. Received cytotoxic medicine or glucocorticoids or other targeted-therapy medicine
             (except for ibrutinib) within 2 weeks prior to T cell collection;

          -  5. With active autoimmune disease;

          -  6. With active infection;

          -  7. With HIV infection, or uncontrolled HBV/HCV/syphilis infection;

          -  8. With known central nervous system lymphoma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wenbin Qian, MD，PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juying Wei, MD</last_name>
    <phone>(+86)13867476302</phone>
    <email>weijuy@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hui Liu, MD,PhD</last_name>
    <phone>(+86)13819198629</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The first affiliated hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenbin Qian, MD,PhD</last_name>
      <phone>(+86)13605801032</phone>
      <email>qianwenb@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 22, 2019</study_first_submitted>
  <study_first_submitted_qc>April 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2019</study_first_posted>
  <last_update_submitted>April 25, 2019</last_update_submitted>
  <last_update_submitted_qc>April 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital of Zhejiang University</investigator_affiliation>
    <investigator_full_name>Wenbin Qian</investigator_full_name>
    <investigator_title>Doctor, Professor</investigator_title>
  </responsible_party>
  <keyword>interleukin 7, Chemokine (C-C Motif) Ligand 19, CAR-T</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

